RXRX Recursion Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why RXRX matters now
Recursion Pharmaceuticals, Inc. (RXRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.56 with -5.32% on the session and $1.59B in market capitalization; recent performance reads 1-month +13.33% and YTD -21.03%.
The latest financial table shown here is Q1 2026, with revenue of $6.5M, net income of $-117.5M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.6%.
The latest indexable market news headline is "Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.50; recent insider activity includes Taylor Ben R filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.67
P/S
21.79
EV/EBITDA
-1.80
DCF Value
$-9.40
FCF Yield
-22.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-34.4%
Operating Margin
-882.9%
Net Margin
-844.5%
ROE
-54.3%
ROA
-41.8%
ROIC
-47.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.5M | $-117.5M | $-0.22 |
| Q4 2025 | $35.5M | $-108.1M | $-0.21 |
| FY 2025 | $74.7M | $-644.8M | $-1.44 |
| Q3 2025 | $5.2M | $-162.3M | $-0.36 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$5.50
Target (Median)
$5.50
Target Range
$5.50 - $5.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.00
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.